Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.

Department of Obstetrics and Gynecology Faculty Hospital Motol 2nd Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Archer DF, Baber RJ, Barlow D, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011;14:302–320. doi: 10.3109/13697137.2011.570590. PubMed DOI

Birkhauser MH, Panay N, Archer DF, et al. Updated recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric. 2008;11(2):108–124. doi: 10.1080/13697130801983921. PubMed DOI

Fait T, Fialova A, Pastor Z. The use of estradiol metered-dose transdermal spray in clinical practice. Climacteric. 2018;21(6):1–5. doi: 10.1080/13697137.2018.1504916. PubMed DOI

Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113(1):65–73. doi: 10.1097/AOG.0b013e31818e8cd6. PubMed DOI

Maclennan AH, Broadbent JL, Lester S, Moore V. Oral estrogen and combined estrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;4:CD002978. doi: 10.1002/14651858.CD002978.pub2. PubMed DOI PMC

Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi: 10.3109/13697137.2015.1129166. PubMed DOI

Attarian H, Hachul H, Guttoso T, Philips B. Treatment of chronic insomnia disorder in menopause: evaluation of literature. Menopause. 2015;22:674–684. doi: 10.1097/GME.0000000000000348. PubMed DOI

Santoro N, Worsley R, Miller KK, et al. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med. 2016;13:305–316. doi: 10.1016/j.jsxm.2015.11.015. PubMed DOI

Wierman ME, Artl W, Basson R, et al. Androgen therapy in women. J Clin Endocrinol Metab. 2014;99:3489–3510. doi: 10.1210/jc.2014-2260. PubMed DOI

Vujovic S, Brincat M, Erel T, et al. EMAS position statement: managing women with premature ovarian failure. Maturitas. 2010;67:91–93. doi: 10.1016/j.maturitas.2010.04.011. PubMed DOI

Utian WH, Woods NF. Impact of hormone therapy on quality of life after menopause. Menopause. 2013;20:1098–1105. doi: 10.1097/GME.0b013e318298debe. PubMed DOI

Emmerson E, Hardman MJ. The role of estrogen deficiency in skin ageing and wound healing. Biogerontology. 2012;13:3–20. doi: 10.1007/s10522-011-9322-y. PubMed DOI

Zetterberg M. Age-related eye disease and gender. Maturitas. 2016;83:19–26. doi: 10.1016/j.maturitas.2015.10.005. PubMed DOI

Nedergaard A, Henriksen K, Karsdal MA, Christiansen C. Menopause, estrogens and frailty. Gynecol Endocrinol. 2013;29:418–423. doi: 10.3109/09513590.2012.754879. PubMed DOI

Hauvais Jarvis F, Manson JE, Stevenson JC, Fonseca VA. MHT and Type 2 Diabetes prevention. Endocrin Rev. 2017;38(3):173–188. doi: 10.1210/er.2016-1146. PubMed DOI PMC

Van Pelt RE, Gavin KM, Kohrt WM. Regulation of body composition and bioenergetics by estrogen. Endocrinol Metab Clin North Am. 2015;44:663–676. doi: 10.1016/j.ecl.2015.05.011. PubMed DOI PMC

Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry. 2015;72:714–726. doi: 10.1001/jamapsychiatry.2015.0111. PubMed DOI PMC

Espeland MA, Shumaker SA, Leng I, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013;173:1429–1436. doi: 10.1001/jamainternmed.2013.7727. PubMed DOI PMC

Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and Alzheimer disease: a prospective cohort study. Neurology. 2017;88:1062–1068. doi: 10.1212/WNL.0000000000003696. PubMed DOI PMC

Fait T, Vrablik M. Coronary heart disease and hormone replacement therapy – from primary and secondary prevention to the window of opportunity. Neuro Endocrinol Lett. 2012;33(Suppl 2):17–21. PubMed

Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in peri-menopausal woman. Eur Heart J. 2007;28:2028–2040. doi: 10.1016/S0140-6736(97)08233-0. PubMed DOI

Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future perspective. Climacteric. 2012;15:217–228. doi: 10.3109/13697137.2012.656401. PubMed DOI PMC

de Lignières B, Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: individual dose/effect relationship. Maturitas. 1982;4(1):67–72. doi: 10.1016/0378-5122(82)90021-4. PubMed DOI

Arbuckle R, Humphrey L, Abraham L. Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in post-menopausal women to inform the development of new patient-reported measurement tools. Maturitas. 2014;78(3):219–227. doi: 10.1016/j.maturitas.2014.04.019. PubMed DOI

Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol. 2005;105(5 Pt 1):1063–1073. doi: 10.1097/01.AOG.0000158120.47542.18. PubMed DOI

Baber RJ, Panay N, Fenton A. And the IMS Writing Group: 2016 IMS Recommendation on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109–150. doi: 10.3109/13697137.2015.1129166. PubMed DOI

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and HRT. Lancet. 1997;350:1047–1059. doi: 10.1016/S0140-6736(97)08233-0. PubMed DOI

Beral V, Banks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360:942–944. doi: 10.1016/S0140-6736(02)11032-4. PubMed DOI

Canonico M, Orger E, Plu-Bureasu G, et al. Estrogen and thromboembolism among postmenopausal women. Circulation. 2007;115:840–845. doi: 10.1161/CIRCULATIONAHA.106.642280. PubMed DOI

Writing Group for the Women’s Health Initiative Investigators. JAMA. 2002;288(3):321–333. doi: 10.1001/jama.288.3.321. PubMed DOI

Bruce D, Robinson J, McWilliams S, et al. Long-term effects of tibolone on mammographic density. Fertil Steril. 2004;82(5):1343–1347. doi: 10.1016/j.fertnstert.2004.03.063. PubMed DOI

Yenen MC, Dede M, Goktolga U, et al. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy. Climacteric. 2003;6:146–150. doi: 10.1080/cmt.6.2.146.150. PubMed DOI

Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. Maturitas. 2005;51:21–28. doi: 10.1016/j.maturitas.2005.02.011. PubMed DOI

Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697–708. doi: 10.1056/NEJMoa0800743. PubMed DOI PMC

Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind randomized, non-inferiority trial. Lancet Oncol. 2009;10(2):135–146. doi: 10.1016/S1470-2045(08)70341-3. PubMed DOI

Schwers J, Eriksson N, Wiquist N, Diczfalusy E. 15α-hydroxylation: a new pathway of estrogen metabolism in the human fetus and newborn. Biochem Biophys Acta. 1965;100:313–316. doi: 10.1016/0304-4165(65)90464-2. PubMed DOI

Visser M, Coellingh Bennink HJT. Clinical application for estetrol. J Steroid Biochem Mol Biol. 2009;114:85–89. doi: 10.1016/j.jsbmb.2008.12.013. PubMed DOI

Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11(Suppl 1):47–58. doi: 10.1080/13697130802073425. PubMed DOI

Lee S, Kim YH, Kim SC, et al. The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer. Obstet Gynecol Sci. 2018;61(5):615–620. doi: 10.5468/ogs.2018.61.5.615. PubMed DOI PMC

Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a SERM: effects on the endometrium, ovarium and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009;16:1109–1115. doi: 10.1097/gme.0b013e3181a818db. PubMed DOI

Pinkerton JV, Komm BS, Mirkin S. Tissue selective estrogen complex combination with basedoxifene/conjugated estrogens as a model. Climacteric. 2013;16:618–628. PubMed

Rahimzadeh P, Imani F, Nafissi N, et al. Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors. Cancer Manag Res. 2018;10:4831–4837. doi: 10.2147/CMAR.S173511. PubMed DOI PMC

Joffe H, Guthrie KA, La croix AZ, et al. Low-dose estrogen and the serotonin-norepinephrin reuptake inhibitor venlafaxine for vasomotor symptoms. JAMA Intern Med. 2014;174:1058–1066. doi: 10.1001/jamainternmed.2014.1891. PubMed DOI PMC

Panday KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer. Lancet. 2005;366:818–824. doi: 10.1016/S0140-6736(05)67215-7. PubMed DOI PMC

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155–1172. doi: 10.1097/GME.0000000000000546. PubMed DOI

Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;12:CD001395. doi: 10.1002/14651858. PubMed DOI PMC

Gold EB, Leung K, Crawford SL, et al. Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms: results from the Study of Women’s Health Across the Nation. Menopause. 2013;20(3):305–314. doi: 10.1097/GME.0b013e31826d2f43. PubMed DOI PMC

Fritz H, Seely D, Flower G, et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One. 2013;8(11):e81968. doi: 10.1371/journal.pone.0081968. PubMed DOI PMC

Powell SL, Gödecke T, Nikolic D, et al. In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent. J Agric Food Chem. 2008;56(24):11718–11726. doi: 10.1021/jf803298z. PubMed DOI PMC

Beer AM, Osmers R, Schnitker J, et al. Efficacy of black cohosh (Cimicifuga racemosa) medicines for treatment of menopausal symptoms – comments on major statements of the Cochrane Collaboration report 2012 “black cohosh (Cimicifuga spp.) for menopausal symptoms (review)”. Gynecol Endocrinol. 2013;29(12):1022–1025. doi: 10.3109/09513590.2013.831836. PubMed DOI

Henneicke-von Zepelin HH. 60 years of Cimicifuga racemosa medicinal products: clinical research milestones, current study findings and current development. Wien Med Wochenschr. 2017;167(7–8):147–159. PubMed PMC

Hellström AC, Muntzing J. The pollen extract Femal – a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause. 2012;19(7):825–829. doi: 10.1097/gme.0b013e31824017bc. PubMed DOI

Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérélys® in the management of women with menopausal symptoms. Gynecol Endocrinol. 2018;34 [In Press] PubMed

The NAMS 2017 Hormone Therapy Position Statement. Menopause. 2017;24(7):728–753. doi: 10.1097/GME.0000000000000921. PubMed DOI

Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015;18:233–240. doi: 10.3109/13697137.2014.975199. PubMed DOI PMC

Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone) Menopause. 2015;22:650–663. doi: 10.1097/GME.0000000000000428. PubMed DOI

Rabley A, O’Shea T, Terry R, et al. Laser therapy for genitourinary syndrome of menopause. Curr Urol Rep. 2018;19(10):83. doi: 10.1007/s11934-018-0831-y. PubMed DOI